Lee's Pharmaceutical Holdings Limited has announced that its subsidiary, China Oncology Focus Limited, has received regulatory approval for Socazolimab, an investigational oncology drug product, from the National Medical Products Administration (NMPA) in Mainland China. This approval allows the marketing of Socazolimab in combination with chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The approval is based on the positive results of a Phase III clinical trial led by Prof. Shun Lu from Shanghai Chest Hospital, which demonstrated significant overall survival benefits for patients treated with Socazolimab.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.